RCMNY
Rubric Capital Management (New York) Portfolio holdings
AUM
$6.22B
This Quarter Return
-0.81%
1 Year Return
+46.93%
3 Year Return
+140.96%
5 Year Return
+327.45%
10 Year Return
–
AUM
$3.79B
AUM Growth
+$3.79B
(+12%)
Cap. Flow
+$467M
Cap. Flow
% of AUM
12.33%
Top 10 Holdings %
Top 10 Hldgs %
44.71%
Holding
74
New
6
Increased
31
Reduced
8
Closed
7
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$65.8M |
| 2 |
Alight
ALIT
|
$62.2M |
| 3 |
Pediatrix Medical
MD
|
$54.7M |
| 4 |
Avis
CAR
|
$49.7M |
| 5 |
Opko Health
OPK
|
$49.4M |
Top Sells
| 1 |
iShares Bitcoin Trust
IBIT
|
$69.7M |
| 2 |
Atmus Filtration Technologies
ATMU
|
$36.5M |
| 3 |
Par Pacific Holdings
PARR
|
$28.6M |
| 4 |
PLYA
Playa Hotels & Resorts
PLYA
|
$26.2M |
| 5 |
ANI Pharmaceuticals
ANIP
|
$22.6M |
Sector Composition
| 1 | Healthcare | 49.8% |
| 2 | Technology | 9.14% |
| 3 | Industrials | 7.83% |
| 4 | Financials | 7.41% |
| 5 | Utilities | 6.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Schrodinger
SDGR
$1.42B
| $60.5M | 1.59% |
3,130,000
+2,131,724
| +214% | +$41.2M |
|
|
27
Opko Health
OPK
$1.1B
| $55.5M | 1.46% |
44,422,304
+39,486,490
| +800% | +$49.4M |
|
|
MREO
28
Mereo BioPharma
MREO
$275M
| $55.1M | 1.44% |
15,307,347
+1,754,350
| +13% | +$6.32M |
|
29
Adeia
ADEA
$1.67B
| $51.9M | 1.36% |
4,640,009
| – | – |
|
30
Adaptive Biotechnologies
ADPT
$1.96B
| $50.7M | 1.33% |
14,000,000
+3,500,000
| +33% | +$12.7M |
|
31
Stratasys
SSYS
$863M
| $50.1M | 1.31% |
5,968,703
+918,703
| +18% | +$7.71M |
|
32
Orthofix Medical
OFIX
$583M
| $49M | 1.28% |
3,694,946
+29,946
| +0.8% | +$397K |
|
33
Dave & Buster's
PLAY
$838M
| $48.8M | 1.28% |
1,225,000
+626,497
| +105% | +$24.9M |
|
34
Teladoc Health
TDOC
$1.37B
| $45.3M | 1.19% |
+4,628,532
| New | +$45.3M |
|
35
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $45.2M | 1.18% |
2,419,103
+223,094
| +10% | +$4.17M |
|
36
NCR Voyix
VYX
$1.76B
| $42.4M | 1.11% |
3,437,030
-1,109,051
| -24% | -$13.7M |
|
37
AAR Corp
AIR
$2.72B
| $41.8M | 1.1% |
575,000
-150,000
| -21% | -$10.9M |
|
|
38
ANI Pharmaceuticals
ANIP
$2.06B
| $38.4M | 1.01% |
603,800
-354,733
| -37% | -$22.6M |
|
39
Xperi
XPER
$272M
| $34M | 0.89% |
4,143,744
+100,000
| +2% | +$821K |
|
40
Zymeworks
ZYME
$1.07B
| $33.3M | 0.87% |
3,917,331
+441,947
| +13% | +$3.76M |
|
41
TransAlta
TAC
$3.57B
| $33.2M | 0.87% |
4,687,158
| – | – |
|
42
GoodRx Holdings
GDRX
$1.49B
| $29.1M | 0.76% |
3,736,802
+1,619,748
| +77% | +$12.6M |
|
43
FTAI Infrastructure
FIP
$479M
| $27.6M | 0.72% |
3,193,530
| – | – |
|
44
Riskified
RSKD
$712M
| $26.7M | 0.7% |
4,173,636
| – | – |
|
45
Cannae Holdings
CNNE
$1.09B
| $25.9M | 0.68% |
1,430,248
+216,031
| +18% | +$3.92M |
|
46
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $18M | 0.47% |
10,400,000
| – | – |
|
47
scPharmaceuticals
SCPH
$296M
| $15.3M | 0.4% |
3,525,000
| – | – |
|
48
Carpenter Technology
CRS
$11.8B
| $15.3M | 0.4% |
139,806
+61,145
| +78% | +$6.7M |
|
49
Trevi Therapeutics
TRVI
$871M
| $15M | 0.39% |
5,026,931
-537,192
| -10% | -$1.6M |
|
50
Shutterstock
SSTK
$746M
| $14.8M | 0.39% |
+381,631
| New | +$14.8M |
|